Phospho-CLDN6 (Tyr219) Antibody

What is CLDN6 and why is phosphorylation at Tyr219 significant?

CLDN6 (Claudin 6) is a member of the tight junction protein family involved in cell-cell adhesion, acting as a physical barrier that prevents solutes and water from passing through the extracellular space . It is classified as an oncofetal antigen that is largely absent in healthy adult tissues but upregulated in several cancer types .

Phosphorylation at tyrosine 219 (Tyr219) is a post-translational modification that regulates CLDN6 function . This specific phosphorylation event may influence protein-protein interactions, subcellular localization, and signaling pathway activation. Research indicates that phosphorylation of tight junction proteins can alter barrier function and potentially contribute to disease processes, making it an important regulatory mechanism to understand in both physiological and pathological contexts .

How are Phospho-CLDN6 (Tyr219) antibodies produced and validated?

Phospho-CLDN6 (Tyr219) antibodies are typically produced by immunizing rabbits with synthetic phosphopeptides derived from the human CLDN6 sequence around the phosphorylation site of tyrosine 219 (T-K-N-Y(p)-V) . These phosphopeptides are often conjugated to carrier proteins like KLH (Keyhole Limpet Hemocyanin) to enhance immunogenicity.

The antibodies undergo purification through affinity chromatography using epitope-specific phosphopeptides . Importantly, non-phospho specific antibodies are removed through chromatography using non-phosphopeptides, ensuring that the final antibody preparation specifically recognizes the phosphorylated form of CLDN6 .

Validation typically includes:

• Western blotting against cell lysates known to express phosphorylated CLDN6

• ELISA assays with phosphorylated and non-phosphorylated peptides

• Testing with blocking peptides to confirm specificity

• Cross-reactivity assessment against other claudin family members

What are the storage and stability requirements for Phospho-CLDN6 (Tyr219) antibodies?

Phospho-CLDN6 (Tyr219) antibodies are typically supplied in a buffer containing phosphate-buffered saline (PBS) with 50% glycerol and 0.02% sodium azide at pH 7.4 . This formulation helps maintain antibody stability during storage.

The recommended storage temperature is -20°C or -80°C . Repeated freeze-thaw cycles should be avoided as they can degrade antibody quality and reduce specificity. When properly stored, the antibodies typically remain stable for 12 months from the date of receipt .

For working solutions, it's advisable to prepare only the amount needed for immediate use and store any remaining stock solution according to the manufacturer's recommendations.

What experimental applications are validated for Phospho-CLDN6 (Tyr219) antibodies?

Phospho-CLDN6 (Tyr219) antibodies have been validated for multiple experimental techniques:

• Western Blot (WB): Detection of phosphorylated CLDN6 in cell lysates, with recommended dilutions of 1:500-1:1000 .

• Immunohistochemistry (IHC): Analysis of tissue sections with recommended dilutions of 1:50-1:200 .

• ELISA: Both traditional and cell-based formats, with peptide ELISA using dilutions of 1:20000-1:40000 .

• Cell-Based Assays: For measuring relative amounts of phosphorylated CLDN6 in cultured cells and screening effects of various treatments or inhibitors .

These applications enable researchers to investigate CLDN6 phosphorylation in various experimental contexts, from basic mechanistic studies to preclinical evaluation of targeted therapies.

How should cell-based assays be designed for optimal detection of phosphorylated CLDN6?

For optimal detection of phosphorylated CLDN6 in cell-based assays:

• Cell Seeding: Seed approximately 20,000 adherent cells per well in a 96-well plate and allow them to reach 75-90% confluence before treatment .

• Fixation Protocol:

  • For adherent cells: Use 4% formaldehyde for 20 minutes at room temperature

  • For suspension cells or loosely attached cells: Use 8% formaldehyde and pre-coat plates with Poly-L-Lysine (10 μg/ml)

• Washing and Blocking Steps:

  • Wash fixed cells with TBS buffer

  • Apply quenching buffer for 20 minutes

  • Block with blocking buffer for 1 hour

• Antibody Application:

  • Primary antibody (Phospho-CLDN6 Tyr219) at appropriate dilution

  • HRP-conjugated secondary antibody against the host species of primary antibody

  • Include controls for total CLDN6 and housekeeping proteins like GAPDH

• Signal Detection:

  • Add appropriate substrate for colorimetric detection

  • Normalize results to cell number using methods like Crystal Violet staining

What controls should be included when working with Phospho-CLDN6 (Tyr219) antibodies?

When designing experiments with Phospho-CLDN6 (Tyr219) antibodies, several controls should be included:

Positive Controls:

• Cell lines known to express phosphorylated CLDN6, such as RAW264.7 cells

• Placenta tissue, which has been documented to express CLDN6

• Lysates from cells treated with agents that enhance tyrosine phosphorylation

Negative Controls:

• Cell lines with low or no CLDN6 expression

• Samples treated with phosphatases to remove phosphorylation

• Blocking peptide controls to confirm antibody specificity

Normalization Controls:

• Antibody against total (non-phosphorylated) CLDN6 to determine the proportion of phosphorylated protein

• Housekeeping proteins like GAPDH for loading control in Western blots

• Cell number normalization using Crystal Violet staining in cell-based assays

How does CLDN6 phosphorylation status relate to cancer progression mechanisms?

Research indicates that CLDN6 plays significant roles in cancer progression through several mechanisms:

• Signaling Pathway Modulation: CLDN6 has been shown to interact with the Hippo signaling pathway by reducing phosphorylation of LATS1/2 and YAP1, affecting YAP1 nuclear translocation and downstream target gene expression . While the specific role of Tyr219 phosphorylation hasn't been fully elucidated, it may influence these interactions.

• EMT Regulation: CLDN6 can promote epithelial-mesenchymal transition (EMT) through the YAP1-snail1 axis in gastric cancer . YAP1 interacts with snail1 to enhance invasive abilities of cancer cells.

• PI3K/AKT Pathway Connection: Knockdown of CLDN6 significantly decreases p-AKT, p-PI3K, and mTOR expression levels in endometrial carcinoma, suggesting that phosphorylation events may be involved in this signaling cascade .

• Proliferation and Migration: High CLDN6 expression correlates with enhanced cell proliferation, colony formation, and invasive/migratory capabilities . The phosphorylation status of CLDN6 may regulate these functions through modulation of protein-protein interactions or subcellular localization.

Understanding the specific role of Tyr219 phosphorylation in these processes represents an important area for future research, potentially revealing new therapeutic strategies targeting CLDN6 phosphorylation.

What cancer types show significant CLDN6 expression and potential Tyr219 phosphorylation?

CLDN6 has been identified as overexpressed in multiple cancer types, with varying degrees of expression:

While the specific phosphorylation status at Tyr219 hasn't been comprehensively characterized across these cancer types, the development of Phospho-CLDN6 (Tyr219) antibodies provides an important tool for such investigations. Given the regulatory role of phosphorylation in protein function, examining Tyr219 phosphorylation patterns could reveal important insights into CLDN6's role in tumor biology.

How can Phospho-CLDN6 (Tyr219) antibodies contribute to development of targeted cancer therapies?

Phospho-CLDN6 (Tyr219) antibodies can play several important roles in the development of targeted cancer therapies:

• Biomarker Development: These antibodies can help identify patients with high levels of phosphorylated CLDN6, potentially indicating activation of specific signaling pathways. This could serve as a biomarker for patient stratification in clinical trials of CLDN6-targeted therapies .

• Mechanism of Action Studies: For antibody-drug conjugates (ADCs) targeting CLDN6, understanding the phosphorylation status might reveal insights into internalization mechanisms and efficacy. Multiple CLDN6-targeted ADCs are in development, including TORL-1-23, which has shown clinical responses in CLDN6-positive tumors .

• Resistance Mechanism Identification: Changes in CLDN6 phosphorylation could be involved in resistance to targeted therapies. Monitoring these changes might help identify adaptive mechanisms and inform combination therapy approaches.

• CAR-T Cell Therapy Development: For CLDN6-directed CAR-T cell therapies like those in the BNT211-01 trial, understanding how phosphorylation affects epitope exposure could improve target recognition. This trial showed promising results in patients with CLDN6-positive solid tumors .

• Dual-Targeting Approaches: Combining drugs targeting CLDN6 with inhibitors of kinases responsible for Tyr219 phosphorylation could potentially enhance therapeutic efficacy through synergistic mechanisms.

What is the relationship between CLDN6 Tyr219 phosphorylation and tight junction dynamics in cancer?

While the specific role of Tyr219 phosphorylation in tight junction dynamics hasn't been fully characterized, several insights can be drawn from research on CLDN6 and related claudins:

• Barrier Function Modulation: Phosphorylation of claudins generally affects tight junction permeability. Tyrosine phosphorylation may alter protein conformation, affecting how CLDN6 interacts with other tight junction components .

• Localization Changes: Phosphorylation events can shift tight junction proteins between membrane and cytoplasmic locations. For CLDN6, Tyr219 phosphorylation might regulate its incorporation into tight junction complexes versus other cellular compartments.

• Signaling Hub Function: Beyond their structural role, tight junctions serve as signaling hubs. CLDN6 has been shown to interact with signaling molecules like LATS1/2 in the Hippo pathway , and phosphorylation at Tyr219 could modulate these interactions.

• EMT Process Influence: Disruption of tight junctions is a hallmark of EMT during cancer progression. CLDN6 promotes EMT through the YAP1-snail1 axis , and phosphorylation status may serve as a switch in this process.

• Cell Adhesion Properties: In cancer, altered adhesion properties contribute to invasive and metastatic potential. Phosphorylation of CLDN6 may alter homophilic or heterophilic interactions at tight junctions, affecting cellular cohesion.

Further research directly addressing the impact of Tyr219 phosphorylation on these aspects of tight junction biology would enhance our understanding of CLDN6's role in cancer progression.

What are common technical challenges when detecting Phospho-CLDN6 (Tyr219)?

Researchers may encounter several technical challenges when working with Phospho-CLDN6 (Tyr219) antibodies:

• Preservation of Phosphorylation State: Phosphate groups can be rapidly hydrolyzed by phosphatases during sample preparation. Always include phosphatase inhibitors in lysis buffers and handle samples at 4°C to minimize dephosphorylation.

• Membrane Protein Solubilization: As a tight junction protein, CLDN6 is embedded in membranes, making complete solubilization challenging. Optimize lysis conditions with appropriate detergents (e.g., RIPA buffer with 0.1-1% SDS or NP-40) to efficiently extract membrane-bound proteins.

• Low Abundance of Phosphorylated Forms: The phosphorylated pool of CLDN6 may represent only a small fraction of total CLDN6. Consider enrichment strategies like immunoprecipitation before Western blotting to increase detection sensitivity.

• Epitope Masking: In fixed tissues or cells, the phospho-epitope may be masked by protein crosslinking or protein-protein interactions. Optimize antigen retrieval methods for IHC applications to enhance epitope accessibility.

• Background Signal: Non-specific binding can occur, especially in IHC applications. Thorough blocking steps and careful antibody titration are essential to achieve optimal signal-to-noise ratios.

How can specificity for phosphorylated versus non-phosphorylated CLDN6 be validated?

Validating antibody specificity for phosphorylated CLDN6 is crucial for experimental rigor. Several approaches can be employed:

• Blocking Peptide Validation: A blocking peptide containing the phosphorylated epitope (T-K-N-Y(p)-V) should abolish antibody binding in Western blot or IHC experiments. In contrast, a non-phosphorylated peptide should not affect binding of a phospho-specific antibody .

• Phosphatase Treatment: Treating one sample with lambda phosphatase before immunoblotting should eliminate signal from a truly phospho-specific antibody while leaving signals from antibodies recognizing total protein unchanged.

• Comparison with Total CLDN6 Antibody: Running parallel samples with antibodies against phosphorylated and total CLDN6 can reveal differences in detection patterns, particularly after treatments that alter phosphorylation status.

• Stimulation/Inhibition Experiments: Treating cells with tyrosine kinase activators versus inhibitors should modulate the signal detected by Phospho-CLDN6 (Tyr219) antibodies if they are truly phospho-specific.

• Mass Spectrometry Validation: For definitive validation, immunoprecipitated proteins detected by the antibody can be analyzed by mass spectrometry to confirm the presence of phosphorylation at Tyr219.

What methodological approaches can enhance detection of low-abundance phosphorylated CLDN6?

For enhanced detection of low-abundance phosphorylated CLDN6:

• Phosphoprotein Enrichment:

  • Immunoprecipitate CLDN6 first, then probe with phospho-tyrosine antibodies

  • Use phospho-tyrosine affinity columns to enrich all phosphorylated proteins before CLDN6 detection

  • Consider TiO₂ or IMAC (Immobilized Metal Affinity Chromatography) for phosphopeptide enrichment when performing mass spectrometry

• Signal Amplification Techniques:

  • Use high-sensitivity detection systems like chemiluminescent substrates with enhanced formulations

  • Consider tyramide signal amplification for IHC applications

  • Explore multiplex fluorescent Western blotting for simultaneous detection of phosphorylated and total CLDN6

• Sample Preparation Optimization:

  • Add phosphatase inhibitor cocktails immediately upon cell lysis

  • Keep samples cold throughout processing

  • Use optimized extraction buffers with chaotropic agents for membrane proteins

• Alternative Detection Platforms:

  • Consider proximity ligation assays (PLA) for in situ detection of protein phosphorylation with increased sensitivity

  • Explore nano-immunoassay platforms like Simple Western for automated, highly sensitive protein detection

  • Use ELISA-based methods with signal amplification for quantitative measurement

• Cellular Models with Enhanced Phosphorylation:

  • Treat cells with pervanadate to inhibit tyrosine phosphatases

  • Use models with constitutively active tyrosine kinases

  • Consider cell lines with CLDN6 overexpression to increase the pool of potentially phosphorylated protein

How might targeting CLDN6 phosphorylation affect the efficacy of CLDN6-directed cancer therapies?

Current CLDN6-directed therapies, such as antibody-drug conjugates and CAR-T cells, primarily target the total protein rather than specific phosphorylated forms . Investigating how Tyr219 phosphorylation affects these therapies could lead to several advancements:

• Enhanced Target Selection: If phosphorylation at Tyr219 correlates with specific cancer phenotypes or treatment responses, it could serve as a more precise biomarker for patient selection than total CLDN6 expression alone.

• Dual-Targeting Strategies: Combining CLDN6-targeted therapies with inhibitors of kinases responsible for Tyr219 phosphorylation might enhance efficacy through synergistic mechanisms, potentially overcoming resistance.

• Phosphorylation-Specific Antibodies: Developing therapeutic antibodies that specifically recognize phosphorylated CLDN6 could potentially increase tumor specificity if the phosphorylated form is more abundant in cancer than normal tissues.

• Dynamic Treatment Monitoring: Monitoring changes in CLDN6 phosphorylation during treatment could provide early indicators of therapeutic response or resistance development, enabling timely intervention.

• Novel Mechanistic Insights: Understanding how phosphorylation affects CLDN6 function in cancer could reveal new therapeutic targets within the same signaling networks, expanding treatment options.

What methods can help elucidate the structural consequences of CLDN6 Tyr219 phosphorylation?

Understanding how Tyr219 phosphorylation affects CLDN6 structure and function requires sophisticated methodological approaches:

• Cryo-Electron Microscopy: This technique could visualize structural differences between phosphorylated and non-phosphorylated CLDN6, particularly in the context of tight junction complexes.

• X-ray Crystallography: Crystallizing phosphorylated versus non-phosphorylated CLDN6 domains could reveal atomic-level structural changes induced by phosphorylation.

• Molecular Dynamics Simulations: Computational approaches can model how phosphorylation alters protein dynamics, flexibility, and interaction potential with binding partners.

• NMR Spectroscopy: For specific domains of CLDN6, NMR could provide insights into local conformational changes induced by phosphorylation.

• Hydrogen-Deuterium Exchange Mass Spectrometry: This technique can identify regions of proteins that exhibit altered solvent accessibility or conformational dynamics upon phosphorylation.

• FRET-Based Approaches: Using fluorescently labeled CLDN6 variants, researchers could measure changes in protein-protein interactions or conformational states associated with phosphorylation status.

• Cross-Linking Mass Spectrometry: This method can capture interaction interfaces that might be altered by phosphorylation, revealing how Tyr219 modification affects CLDN6's interaction network.

How does CLDN6 Tyr219 phosphorylation compare with phosphorylation sites on other claudin family members?

Comparative analysis of phosphorylation across claudin family members could yield important insights:

• Sequence Conservation: While CLDN6 shares high homology with CLDN9 (only 3 extracellular amino acids different) , the conservation of Tyr219 and surrounding residues across other claudins would indicate functional importance of this phosphorylation site.

• Functional Consequences: Phosphorylation at equivalent sites in different claudins might have distinct functional outcomes based on their tissue distribution and binding partners. Systematic comparison could reveal claudin-specific versus shared regulatory mechanisms.

• Kinase Specificity: Different tyrosine kinases may target specific claudins based on recognition sequences surrounding the phosphorylation site. Identifying the kinases responsible for Tyr219 phosphorylation in CLDN6 versus equivalent sites in other claudins could reveal regulatory networks.

• Evolutionary Perspective: Analyzing the conservation of phosphorylation sites across species could highlight functionally important regulatory mechanisms that have been preserved during evolution.

• Disease Relevance: Comparing phosphorylation patterns of different claudins in cancer versus normal tissues could reveal whether Tyr219 phosphorylation of CLDN6 represents a unique cancer-associated modification or is part of a broader pattern of claudin dysregulation.